Stromal Fibroblasts in Tertiary Lymphoid Structures: A Novel Target in Chronic Inflammation.

Détails

Ressource 1Télécharger: fimmu-07-00477.pdf (2054.66 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_4CBAF2590EBE
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Stromal Fibroblasts in Tertiary Lymphoid Structures: A Novel Target in Chronic Inflammation.
Périodique
Frontiers in Immunology
Auteur(s)
Barone F., Gardner D.H., Nayar S., Steinthal N., Buckley C.D., Luther S.A.
ISSN
1664-3224
ISSN-L
1664-3224
Statut éditorial
Publié
Date de publication
2016
Peer-reviewed
Oui
Volume
7
Pages
477
Langue
anglais
Résumé
Tertiary lymphoid structures (TLS) are organized aggregates of lymphocytes, myeloid, and stromal cells that provide ectopic hubs for acquired immune responses. TLS share phenotypical and functional features with secondary lymphoid organs (SLO); however, they require persistent inflammatory signals to arise and are often observed at target sites of autoimmune disease, chronic infection, cancer, and organ transplantation. Over the past 10 years, important progress has been made in our understanding of the role of stromal fibroblasts in SLO development, organization, and function. A complex and stereotyped series of events regulate fibroblast differentiation from embryonic life in SLOs to lymphoid organ architecture observed in adults. In contrast, TLS-associated fibroblasts differentiate from postnatal, locally activated mesenchyme, predominantly in settings of inflammation and persistent antigen presentation. Therefore, there are critical differences in the cellular and molecular requirements that regulate SLO versus TLS development that ultimately impact on stromal and hematopoietic cell function. These differences may contribute to the pathogenic nature of TLS in the context of chronic inflammation and malignant transformation and offer a window of opportunity for therapeutic interventions in TLS associated pathologies.

Mots-clé
tertiary lymphoid structures, chemokines, tumor necrosis factor-alpha, lymphotoxin alpha1, beta2 heterotrimer, fibroblasts
Pubmed
Web of science
Open Access
Oui
Création de la notice
01/12/2016 8:07
Dernière modification de la notice
20/08/2019 14:01
Données d'usage